Key facts
- xFOREST Therapeutics’s last known valuation is $53.5M (Jan 2025).
- It has raised $7.3M; the latest was Secondary Transaction - Private ($6.0M) in Feb 2026.
- Notable investors include J-Startup, ANRI, Biojent, Keystone Partners (Tokyo), Kyoto University Venture Incubation and Capital Investment — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for xFOREST Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for xFOREST Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About xFOREST Therapeutics
Developer of RNA-targeted small-molecule therapeutics designed to modulate RNA structure and splicing in diseases not addressed by conventional approaches. The company offers discovery platforms for screening selective RNA-structure binders and splicing modulators, enabling pharmaceutical partners and internal research teams to identify targeted RNA interactions and advance therapeutic development across multiple disease areas.
- Sector
- Healthcare
- HQ
- Kyoto, Japan
- Founded
- 2020
- Employees
- 30
- Website
- xforestx.com/
- Ownership
- Privately Held (backing)
xFOREST Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in xFOREST Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on xFOREST Therapeutics in its N-PORT filings yet. We sweep new filings monthly.